Why the Oncosil (ASX:OSL) share price finished the day higher today

The Oncosil Medical Ltd (ASX: OSL) share price finished in positive territory during late-afternoon trade. We take a closer look into why.

| More on:
China war ASX shares iron ore price record asx share price rise represented by a rising arrow on green chart

Image source: Getty Images

The Oncosil Medical Ltd (ASX: OSL) share price finished in positive territory during late-afternoon trade. This comes after the company announced it has received regulatory approval from an important strategic market.

At market close, the medical device company’s shares ended the day at 9.8 cents, up 4.2%.

New market opportunity

Investors appear pleased with the company’s latest update, sending Oncosil shares higher towards the end of the day.

In the statement to the ASX, Oncosil advised it has been granted regulatory clearance to market and sell the Oncosil device in Hong Kong. This follows the recent approvals received in Singapore and Malaysia last year.

Oncosil stated the regulatory clearance came from the Medical Device Division which operates under the Department of Health in Hong Kong.

The company’s Oncosil device will be targeted for the treatment of locally advanced pancreatic cancer (LAPC). The disease represents around one-third of the cases of pancreatic cancer and has a median survival of 9 months.

Oncosil stated that Hong Kong is an important market in the Association of Southeast Asian Nations (ASEAN) commercialisation strategy. The country has a small number of hospitals that can provide treatment of LAPC. In addition, healthcare spending per capita is considered as high when compared to other Asian markets.

Furthermore, the company also revealed that it has begun commercial sales in New Zealand, although no sales figures were given. It is also awaiting the outcome of its application lodged to the Australian Therapeutic Goods Administration to sell its device.

Oncosil share price snapshot

Despite today’s positive announcement, the Oncosil share price has been a poor performer over the past 12 months, down 13%. When looking at year-to-date comparisons, the company’s shares have also dropped 22%.

Based on today’s prices, Oncosil has a market capitalisation of around $75 million, with over 807 million shares on issue.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Imugene (ASX:IMU) share price leaps 10% on new Roche deal

Key Points Imugene shares rocket on back of new supply agreement with Roche Clinical trial of PD1-Vaxx will be combined …

Read more »

Lab technician analyses a sample in a laboratory for a clinical trial
Healthcare Shares

Race Oncology (ASX:RAC) share price rises following preclinical discovery

Key points The Race Oncology share price is up as high as 2.8% today A new discovery relating to heart …

Read more »

shocked man with hands over his face with a declining graph in background representing falling CleanSpace share price
Healthcare Shares

Why the AnteoTech (ASX:ADO) share price is plummeting 23% on Friday

Key Points AnteoTech shares sink on additional request for information by the TGA The company submitted a performance report last …

Read more »

Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx
Healthcare Shares

Why the Imugene (ASX:IMU) share price advanced 5% on market open

Key points Imugene share price soared 5% on the back of European patent approval This is further intellectual protection for …

Read more »

A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today
Earnings Results

ResMed (ASX:RMD) share price on watch after Q2 update disappoints

Key points ResMed delivered solid revenue and profit growth in the second quarter A major competitor product recall boosted demand …

Read more »

Lab worker puts hands in the air and dances around
Healthcare Shares

Here’s why the Rhythm Biosciences (ASX:RHY) share price soared 8% today

Key points The Rhythm Biosciences share price finished the day up by more than 8% after earlier jumping by 19% …

Read more »

gloved hand holding covid-19 vaccine against backdrop of australian flag
Healthcare Shares

Own CSL (ASX:CSL) shares? Here’s why the company is moving on from COVID research

CSL Limited (ASX: CSL) shares are joining the broader ASX selloff today, down 3.93% to $248.20 per share. The S&P/ASX …

Read more »

Graph showing a fall in share price.
Healthcare Shares

Why is the Cochlear (ASX:COH) share price tumbling 5% on Thursday?

Key points Cochlear is one of the worst performing ASX 200 healthcare stocks on Thursday Right now, its share price …

Read more »